Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-12-21 Capital/Financing Update
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release from Tetra Bio-Pharma announcing that the company is on track to receive government funding to accelerate the development of a drug (ARDS-003) targeting sepsis and acute respiratory distress syndrome (ARDS). It provides detailed information about the drug development, market context, and the company's strategy. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a regulatory filing. It is an update on financing related to government funding for drug development, which fits best under Capital/Financing Update (CAP). The document is over 10,000 characters and contains substantive information about the financing and development program, not just an announcement of a report or a certification. Therefore, the most appropriate classification is CAP with high confidence.
2020-12-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a milestone related to Tetra Bio-Pharma's regulatory interactions with the FDA regarding the development and approval pathway of an inhaled THC drug. It discusses clinical development plans, regulatory strategy under the 505(b)(2) pathway, and future commercialization plans. There are no financial statements, earnings data, or detailed financial analysis. The document is not a report but an update on regulatory and development progress. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is primarily a regulatory and corporate update announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-12-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release providing an update on the market potential and commercial strategy for a pharmaceutical product (QIXLEEF™) by Tetra Bio-Pharma. It discusses estimated sales forecasts, clinical trial phases, regulatory approval timelines, and potential partnerships. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports. The content is focused on business development and market outlook rather than financial results or governance. It is not a report itself but an announcement/update on commercial and strategic plans. This fits best under Capital/Financing Update (CAP) as it relates to potential commercial partnerships and market potential, which are typical of financing or capital-related updates. The document length (7214 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is CAP with high confidence.
2020-12-07 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a major milestone in the development of a COVID-19 therapeutic drug candidate by Tetra Bio-Pharma. It details the completion of Investigational New Drug (IND)-enabling toxicology studies, clearing the way for human clinical trials. The content focuses on scientific and regulatory progress rather than financial results, management changes, or shareholder voting. It is not a financial report, earnings release, or regulatory filing. The document is a corporate announcement about a development milestone and clinical trial readiness, which fits best under the category of a general regulatory announcement or miscellaneous corporate update. Given the absence of financial data, voting results, or detailed management information, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2020-12-02 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a company update on recent milestones achieved by Tetra Bio-Pharma, including clinical trial initiations, drug development progress, manufacturing scale-up, and regulatory plans. It references the company's Annual General Meeting (AGM) from June 2020 but does not contain the AGM materials themselves. The text is a narrative update on operational and developmental progress rather than a formal financial report, earnings release, or regulatory filing. It is not a transcript of a call, nor a detailed investor presentation or management discussion. The document is a corporate milestone update, which typically falls under general regulatory announcements or company updates. Given the content and style, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like earnings release, annual report, or capital update.
2020-11-16 English
News release - English.pdf
Regulatory Filings
2020-11-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.